Purchase textbook

Clinical Studies and Therapies in Parkinson's Disease,

Edition 1 Translations from Preclinical Models

Editors: By Juan Segura-Aguilar

Publication Date: 16 Jun 2021

0 Reviews

Conformance

PDF/UA-1
The publication was certified on 20250728
For queries regarding accessibility information, contact [email protected]

Ways Of Reading

This e-publication is accessible to the full extent that the file format and types of content allow, on a specific reading device, by default, without necessarily including any additions such as textual descriptions of images or enhanced navigation.

Navigation

The contents of the PDF have been tagged to permit access by assistive technologies as per PDF-UA-1 standard.
Page breaks included from the original print source

Additional Accessibility Information

The language of the text has been specified (e.g., via the HTML or XML lang attribute) to optimise text-to-speech (and other alternative renderings), both at the whole document level and, where appropriate, for individual words, phrases or passages in a different language.

Note

This product relies on 3rd party tooling which may impact the accessibility features visible in inspection copies. All accessibility features mentioned would be present in the purchased version of the title.

More than 50 years have passed since the use of L-dopa in the palliative treatment of Parkinson’s disease, but it remains the most common treatment despite inducing severe side effects such as dyskinesia after 4–6 years of use. Numerous preclinical investigations based on endogenous neurotoxin models have promised various therapies for Parkinson’s disease, but these efforts have failed when attempting to transfer these successful results to preclinical studies. Although several publications have warned of these failures, the scientific community remains mostly unaware, and there is a need to focus their efforts on potential therapeutics that can slow or halt development of the disease.

Clinical Studies and Therapies in Parkinson’s Disease: Translations from Preclinical Models analyzes preclinical models based on exogenous neurotoxins and why they have failed. Neuroscientists, neurologists, and neuropharmacologists will benefit greatly from the book’s discussion of these newer models, their benefits, and the need for their implementation. This book also provides the basic concepts of dopamine metabolism for students taking courses in neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine.

Key Features

Reviews Parkinson's disease classification, pharmacological therapies, and nonmotor and motor symptoms
Analyzes preclinical models of Parkinson’s disease therapies based on exogenous neurotoxins and why they have failed
Reviews genetic preclinical models based on genetic mutations and endogenous neurotoxins
Proposes a more physiological model directly related to the metabolism of dopaminergic neurons
Provides the basic concepts and mechanisms of dopamine metabolism

About the author

By Juan Segura-Aguilar, Professor, University of Chile, Santiago, Chile

ISBN: 9780128221204

Page Count: 306

Retail Price :

9780128037836; 9780124051959; 9780123740281

Neuroscientists, neurologists, neuropharmarcologists, and students studying neurochemistry, neuroscience, neuropharmacology, biochemistry, and medicine